MedTrace Logo

Influence of Caffeine Consumption on the Human Circadian System

NCT05409339 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-06-08

No results posted yet for this study

Summary

Surveys indicate that 85% of the adult population consume caffeine on a daily basis. Caffeine acts on sleep homeostatic mechanisms by antagonizing the sleep factor adenosine. Whether and how caffeine also impacts on the circadian regulation of sleep and -wakefulness is fairly unexplored. This study quantifies the influence of regular caffeine intake and its cessation on circadian promotion of sleep and wakefulness, on circadian hormonal markers, well-being, neurobehavioral performance and associated cerebral mechanisms. The knowledge is expected to contribute important insights on recent societal changes in sleep-wake behavior (e.g., shorter sleep duration and delayed sleep phase) and the related increase in people suffering from sleep problems.

Conditions

  • Caffeine
  • Caffeine Withdrawal
  • Sleep
  • Circadian Rhythm

Interventions

DRUG

Caffeine

150 mg caffeine, 3 times/day (wakeup + 45 min, +255 min, and +475 min)

DRUG

Placebo

Mannitol, 3 times/day (wakeup + 45 min, +255 min, and +475 min)

Sponsors & Collaborators

  • Swiss National Science Foundation

    collaborator OTHER

  • Psychiatric Hospital of the University of Basel

    lead OTHER

Principal Investigators

  • Carolin Reichert, Dr. · UPK Basel

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-05-09
Primary Completion
2017-10-08
Completion
2017-12-17

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05409339 on ClinicalTrials.gov